EAPH (Easton Pharmaceuticals) Debt-to-Asset : 0.29 (As of Sep. 2021)

View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals Debt-to-Asset?

Easton Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $0.00 Mil. Easton Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $2.84 Mil. Easton Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2021 was $9.97 Mil. Easton Pharmaceuticals's debt to asset for the quarter that ended in Sep. 2021 was 0.28.

Easton Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Easton Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals Debt-to-Asset Chart

Easton Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec18

Dec19

Dec20

Debt-to-Asset

Get a 7-Day Free Trial

0.21

0.49

0.24

Easton Pharmaceuticals Quarterly Data
	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21
Debt-to-Asset	Get a 7-Day Free Trial															0.49	0.24	0.28	0.28	0.29

Competitive Comparison of Easton Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Easton Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Easton Pharmaceuticals's Debt-to-Asset falls into.

Easton Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Easton Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	2.482)	/	10.192
	=	0.24

Easton Pharmaceuticals's Debt-to-Asset for the quarter that ended in Sep. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	2.837)	/	9.968
	=	0.28

Easton Pharmaceuticals (OTCPK:EAPH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Easton Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Easton Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8

Website

http://www.eastonpharmaceuticalsinc.com

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.